2. Prostate cancer is still a leading cancer killer for men in the U.S. ... 2. Just because you are diagnosed with prostate cancer, doesn't mean you need to treat it.
An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment
Researchers noted that total cancer rates were likely influenced by the increased surveillance for prostate-specific antigen and subsequent diagnoses of prostate cancer. ... The significant reduction in total cancer minus prostate cancer suggests that
HPV is the most common sexually-transmitted disease and aside from causing cervical cancer is also the cause of genital warts. ... to 26 that immunize them from the subtypes of HPV that cause cancer.
to. When it came back at 4.10 ng/dL (threshold 4.00), he went for biopsy (what else to do?) which showed low grade, gland-confined prostate cancer. ... Or George, who dutifully came yearly for his digital rectal exam, got his PSA, and when his biopsy
Cabazitaxel (Jevtana), a chemotherapy drug used with prednisone for prostate cancer. ... It is the first treatment for advanced, hormone-refractory prostate cancer that has worsened during or after treatment with docetaxel.
African-American men have a much higher rate of aggressive prostate cancer and men in high risk groups may get higher benefit from these tests. ... The American Cancer Society estimates that 241, 740 men will be diagnosed with prostate cancer this year,
For prostate cancer, the SEER data show a median age of 67 years at diagnosis, and for death from prostate cancer, 80 years. ... So the potential number of life-years saved by early detection and intervention is, on average, greater for breast cancer
men standing on a beach with the words “Free Prostate Cancer Screening” printed below in an attractive font. ... Preventive Services Task Force came out with their strongest statement ever, saying they recommended against prostate cancer screening.
Sipuleucel-T (Provenge), autologous cellular immunotherapy approved to treat asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment. ... cancer. Most of the studies